Alexandra Drakaki

Alexandra Drakaki

UNVERIFIED PROFILE

Are you Alexandra Drakaki?   Register this Author

Register author
Alexandra Drakaki

Alexandra Drakaki

Publications by authors named "Alexandra Drakaki"

Are you Alexandra Drakaki?   Register this Author

53Publications

2847Reads

49Profile Views

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature.

Transplant Proc 2019 Nov 15;51(9):3053-3058. Epub 2019 Oct 15.

Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, California, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.08.002DOI Listing
November 2019

To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.

Cancer 2019 Oct 18;125(20):3506-3513. Epub 2019 Jul 18.

Division of Hematology and Oncology, David Geffen School of Medicine, Los Angeles, California.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32326
Publisher Site
http://dx.doi.org/10.1002/cncr.32326DOI Listing
October 2019

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.

Urol Oncol 2019 Sep 28;37(9):577.e9-577.e16. Epub 2019 Mar 28.

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.03.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698401PMC
September 2019

Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.

World J Urol 2019 Sep 13. Epub 2019 Sep 13.

Department of Urology, University Medicine at the Ernst-Moritz-Arndt-University Greifswald, F. Sauerbruch Str, 17475, Greifswald, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02930-4DOI Listing
September 2019

Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors.

Urol Oncol 2019 Sep 16. Epub 2019 Sep 16.

Institute of Urologic Oncology (IUO) at UCLA, Department a of Urology, David Geffen School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.08.016DOI Listing
September 2019

Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success.

Cancer Treat Res Commun 2018 17;17:1-7. Epub 2018 Aug 17.

Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183007
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2018.08.002DOI Listing
May 2019

Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art.

Cancer Treat Res Commun 2018 22;17:8-12. Epub 2018 Aug 22.

Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24682942183007
Publisher Site
http://dx.doi.org/10.1016/j.ctarc.2018.08.001DOI Listing
May 2019

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Cancer Immunol Immunother 2019 May 21;68(5):743-751. Epub 2019 Feb 21.

Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02316-w
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02316-wDOI Listing
May 2019

Second primary lung cancer in United States Cancer Survivors, 1992-2008.

Cancer Causes Control 2019 May 21;30(5):465-475. Epub 2019 Mar 21.

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-019-01161-7DOI Listing
May 2019

Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era.

Case Rep Oncol Med 2019 25;2019:8349793. Epub 2019 Mar 25.

UCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USA.

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crionm/2019/8349793/
Publisher Site
http://dx.doi.org/10.1155/2019/8349793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452553PMC
March 2019

Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.

World J Urol 2019 Jan 1;37(1):115-123. Epub 2018 Jun 1.

Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2355-yDOI Listing
January 2019

Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?

Urol Oncol 2019 01 13;37(1):63-70. Epub 2018 Nov 13.

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439183040
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2018.10.018DOI Listing
January 2019

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:284-300. Epub 2019 May 17.

4 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_237449DOI Listing
January 2019

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.

Urol Oncol 2018 12 15;36(12):527.e13-527.e19. Epub 2018 Sep 15.

Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, CA; Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.08.009DOI Listing
December 2018

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

World J Urol 2018 Nov 11;36(11):1825-1833. Epub 2018 May 11.

Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2327-2DOI Listing
November 2018

Not Just Another Infection.

Am J Med 2018 11 26;131(11):e463-e464. Epub 2018 Jul 26.

Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine, University of California Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2018.06.029DOI Listing
November 2018

Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma.

Clin Pract 2018 Oct 4;8(4):1097. Epub 2018 Dec 4.

Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/cp.2018.1097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291742PMC
October 2018

Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.

Eur Urol 2018 07 9;74(1):119-121. Epub 2018 Feb 9.

Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.01.036DOI Listing
July 2018

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer.

Mol Cancer Ther 2018 07 27;17(7):1430-1440. Epub 2018 Apr 27.

Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1049DOI Listing
July 2018

Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Eur Urol 2018 06 9;73(6):981. Epub 2018 Feb 9.

Institute of Urologic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.01.023DOI Listing
June 2018

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.

Clin Genitourin Cancer 2018 04 3;16(2):e269-e276. Epub 2017 Nov 3.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.10.011DOI Listing
April 2018

Trends in urinary diversion after radical cystectomy for urothelial carcinoma.

World J Urol 2018 Mar 3;36(3):409-416. Epub 2018 Jan 3.

Department of Urology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-017-2169-3
Publisher Site
http://dx.doi.org/10.1007/s00345-017-2169-3DOI Listing
March 2018

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Urol Oncol 2018 02 2;36(2):79.e19-79.e26. Epub 2017 Nov 2.

Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, CA; Institute of Urologic Oncology, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439173054
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2017.10.009DOI Listing
February 2018

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Urol Oncol 2018 02 8;36(2):78.e21-78.e28. Epub 2017 Nov 8.

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439173052
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2017.09.030DOI Listing
February 2018

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

J Urol 2018 01 4;199(1):43-52. Epub 2017 May 4.

Institute of Urologic Oncology, Department of Urology, University of California, Los Angeles, Los Angeles, California; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.04.092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720927PMC
January 2018

Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.

Urol Oncol 2018 01 20;36(1):9.e1-9.e9. Epub 2017 Oct 20.

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.001DOI Listing
January 2018

Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.

BMJ Case Rep 2017 Oct 4;2017. Epub 2017 Oct 4.

Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2017-220415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652350PMC
October 2017

Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection.

AIDS 2017 09;31(14):1925-1934

aDivision of Infectious Diseases bVatche and Tamar Manoukian Division of Digestive Diseases cDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA dCenter for Systems Biomedicine, David Geffen School of Medicine at UCLA eUCLA AIDS Institute, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAD.0000000000001582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578872PMC
September 2017

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Mol Cancer Ther 2017 02 30;16(2):376-387. Epub 2016 Nov 30.

Department of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335870PMC
February 2017

Immunotherapy for the Treatment of Urothelial Carcinoma.

J Urol 2017 01 25;197(1):14-22. Epub 2016 Jul 25.

Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California; Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2016.02.3005DOI Listing
January 2017

Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Cancer 2016 10 5;122(19):3075-86. Epub 2016 Jul 5.

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192520PMC
October 2016

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

J Clin Oncol 2016 09 6;34(26):3119-25. Epub 2016 Jun 6.

Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.9761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569690PMC
September 2016

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification.

Case Rep Oncol 2016 May-Aug;9(2):298-304. Epub 2016 Jun 11.

Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, Calif., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000445827DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924467PMC
July 2016

A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma.

BMC Cancer 2016 06 3;16:353. Epub 2016 Jun 3.

Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, UCLA, 650 Charles E. Young Dr., CHS 44-133, Los Angeles, CA, 90095-7278, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2384-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893280PMC
June 2016

The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors.

Expert Opin Biol Ther 2015 12;15(8):1205-20. Epub 2015 Jun 12.

UCLA's Jonsson Comprehensive Cancer Center, Department of Hematology/Oncology , 8-684 Factor Building, Box 951781, Los Angeles, CA 90095-1781 , USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1050375DOI Listing
February 2016

Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

BMC Cancer 2015 Jul 24;15:542. Epub 2015 Jul 24.

Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, 650 Charles E. Young Dr., CHS 44-133, Los Angeles, CA, 90095-7278, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-015-1562-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512159PMC
July 2015

MicroRNA-gene signaling pathways in pancreatic cancer.

Biomed J 2013 Sep-Oct;36(5):200-8

Center for Systems Biomedicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2319-4170.119690DOI Listing
September 2014

Therapeutically targeting microRNAs in liver cancer.

Curr Pharm Des 2013 ;19(7):1180-91

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161213804805658DOI Listing
August 2013

Novel immunotherapies in GU malignancies.

Curr Oncol Rep 2013 Jun;15(3):224-31

Beth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11912-013-0306
Web Search
http://link.springer.com/10.1007/s11912-013-0306-8
Publisher Site
http://dx.doi.org/10.1007/s11912-013-0306-8DOI Listing
June 2013

MicroRNA Gene Networks in Oncogenesis.

Curr Genomics 2009 Mar;10(1):35-41

Caritas St Elizabeth Medical Center, Tufts University, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920209787581299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699834PMC
March 2009

Epigenetic regulation of hTERT promoter in hepatocellular carcinomas.

Int J Oncol 2009 Feb;34(2):391-9

Institute of Biomedical Research and Technology, Larissa, Greece.

View Article

Download full-text PDF

Source
February 2009